Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
US7318927B2 · kind B2 · utility
4Cited by
2References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2002 |
| Grant date | Jan 15, 2008 |
| Priority date | — |
| Expiry date | Oct 15, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16322
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.